Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 4,129 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Neck Neoplasms Clear all

Conditions: Esophageal Cancer, Gastric Adenocarcinoma, HER2 Gene Mutation
Interventions: Pembrolizumab, Trastuzumab, Oxaliplatin, Capecitabine, 5-Fluorouracil, Docetaxel, Nutrition questionnaires (optional), stool and saliva samples (optional); Drug · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 10
States / cities: Boston, Massachusetts • Basking Ridge, New Jersey • Middletown, New Jersey + 7 more

Conditions: Prostate Cancer, Colorectal Cancer, Breast Cancer, Cervical Cancer, Lung Cancer
Interventions: Navigation Services, Cancer education; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: Not listed
Enrollment: 1,800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 2
States / cities: Great Falls, Montana • Salt Lake City, Utah

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Telisotuzumab Adizutecan, Pembrolizumab, Carboplatin, Cisplatin, Fluorouracil; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Duarte, California • Newnan, Georgia

Conditions: Cervical Cancer, Metastatic Cervical Cancer
Interventions: Pembrolizumab, Lenvatinib; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Augusta, Georgia • Hackensack, New Jersey

Conditions: HPV
Interventions: Self-swab for genital HPV; Diagnostic Test
Lead sponsor: University of Hawaii; Other
Eligibility: 25 Years and older · Female only
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Renal Cell Carcinoma, Small-cell Lung Cancer, Cutaneous Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Merkel Cell Carcinoma
Interventions: GEN-011, IL-2, Fludarabine, Cyclophosphamide; Biological · Drug
Lead sponsor: Genocea Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 8
States / cities: Gilbert, Arizona • Tampa, Florida • Chicago, Illinois + 4 more

Conditions: Esophageal Cancer, Stomach Cancer
Interventions: Bevacizumab, Docetaxel, Cisplatin, Irinotecan; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Metastatic Cancer, Cervical Cancer
Interventions: Lorigerlimab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Uterine Cervical Cancer
Interventions: Not listed
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years to 26 Years · Female only
Enrollment: 191 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 4
States / cities: Athens, Ohio • Gallipolis, Ohio • Logan, Ohio + 1 more

Conditions: Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck
Interventions: Ozuriftamab Vedotin, Pembrolizumab, Evalstotug (BA3071), Cetuximab; Biological
Lead sponsor: BioAtla, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 7
States / cities: Los Angeles, California • Newark, Delaware • Chicago, Illinois + 4 more

Conditions: Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma, Head and Neck
Interventions: Mitomycin-C, Pegfilgrastim; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Dysphagia
Interventions: Neurotech NT2000 Neuromuscular Electrical Stimulation (NMES); Device
Lead sponsor: Boston Medical Center; Other
Eligibility: 21 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 14
States / cities: Scottsdale, Arizona • San Diego, California • Evanston, Illinois + 8 more

Conditions: Esophageal Cancer, Gastric Cancer
Interventions: cisplatin, epirubicin hydrochloride, fluorouracil, oxaliplatin, adjuvant therapy, neoadjuvant therapy; Drug · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Trismus
Interventions: Dynasplint Trismus System, Tongue Depressors; Device · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Mouth Cancer, Lip Cancer, Throat Cancer, Lip Neoplasms, Head and Neck Cancers
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2013
U.S. locations: 1
States / cities: Stanford, California

Conditions: Squamous Cell Carcinoma of the Head and Neck
Interventions: MAGE-A3, HPV-16 vaccine; Biological
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 80 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms
Interventions: Intensity Modulated Radiotherapy (IMRT), Cisplatin (or alternative), Assessment for surgical evaluation; Radiation · Drug · Procedure
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 5
States / cities: Gainesville, Florida • Chapel Hill, North Carolina • Hendersonville, North Carolina + 2 more

Conditions: Cervical Cancer
Interventions: Demographic Form and Semi-Structured Interview Guide; Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 21 Years to 65 Years · Female only
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Head and Neck Neoplasms, Emergency Department Presentation, Head and Neck Cancer (H&N)
Interventions: Community Health Support Specialist (CHSS) Navigation; Behavioral
Lead sponsor: University of Tennessee; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Orlando, Florida • Memphis, Tennessee

Conditions: Stage IA Cervical Cancer, Stage IA1 Cervical Cancer, Stage IA2 Cervical Cancer, Stage IB Cervical Cancer, Stage IB1 Cervical Cancer, Stage IB2 Cervical Cancer, Stage IB3 Cervical Cancer
Interventions: Fludeoxyglucose F-18, Gadobutrol, Magnetic Resonance Imaging, Positron Emission Tomography; Other · Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cancer
Interventions: capecitabine, radiation therapy; Drug · Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 17
States / cities: Scottsdale, Arizona • Urbana, Illinois • Cedar Rapids, Iowa + 14 more

Conditions: Head and Neck Cancer
Interventions: celecoxib; Drug
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 2
States / cities: Columbus, Ohio • Houston, Texas

Conditions: Dysplasia, Carcinoma of the Oral Cavity, Carcinoma of the Oropharynx
Interventions: HPPH; Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Advanced or Metastatic Merkel Cell Carcinoma, Advanced or Metastatic Cutaneous Squamous Cell Carcinoma, Advanced or Metastatic Melanoma, Advanced or Metastatic Head and Neck Squamous Cell Carcinoma, Advanced or Metastatic Solid Tumors
Interventions: Cavrotolimod, Pembrolizumab, Cemiplimab; Drug · Biological
Lead sponsor: Exicure, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 26
States / cities: Tucson, Arizona • Orange, California • San Francisco, California + 21 more

Search by objective public record fields.

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

Reducing Cancer Disparities for American Indians in the Rural Intermountain West

A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Pembrolizumab and Lenvatinib in Advanced Cervical Cancer

Self-Collected Swabs for Primary Human Papilloma Virus (HPV) Screening

TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy

Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer

Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)

Community Awareness, Resources and Education (CARE II): Project 3

A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies

Efficacy of Electrical Stimulation for Dysphagia in Head & Neck Cancer Patients

Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach

Dynasplint Therapy for Trismus in Head and Neck Cancer

A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations

0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck

De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study

Vietnamese Women's Health Project III

Access to Care Pilot for ED-Presenting Head and Neck Cancer Patients (ENRICH-HNC)

PET/MRI Scan for the Evaluation of Resectable Stage IA1-IB3 Cervical Cancer

Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer

Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer

A Trial of Photodynamic Therapy With HPPH for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Oral Cavity and/or Oropharynx

Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors